An Anti-CD7 Antibody–Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL)
Biomolecules · 15.01.2024 · 14 (1) · 106
DOI: 10.3390/biom14010106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 15.01.2024. Verfasst von Shiqi Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Burkitt Lymphoma, Immunoconjugates, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, 1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University, the Frontiers Medical Center, Tianfu Jincheng Laboratory Foundation.
Abstract (Originalsprache)
Acute T-lymphoblastic leukemia (T-ALL) is a type of leukemia that can occur in both pediatric and adult populations. Compared to acute B-cell lymphoblastic leukemia (B-ALL), patients with T-cell T-ALL have a poorer therapeutic efficacy. In this study, a novel anti-CD7 antibody–drug conjugate (ADC, J87-Dxd) was successfully generated and used for T-ALL treatment. Firstly, to obtain anti-CD7 mAbs, we expressed and purified the CD7 protein extracellular domain. Utilizing hybridoma technology, we obtained three anti-CD7 mAbs (J87, G73 and A15) with a high affinity for CD7. Both the results of immunofluorescence and Biacore assay indicated that J87 (KD = 1.54 × 10−10 M) had the highest affinity among the three anti-CD7 mAbs. In addition, an internalization assay showed the internalization level of J87 to be higher than that of the other two mAbs. Next, we successfully generated the anti-CD7 ADC (J87-Dxd) by conjugating DXd to J87 via a cleavable maleimide-GGFG peptide linker. J87-Dxd also possessed the ability to recognize and bind CD7. Using J87-Dxd to treat T-ALL cells (Jurkat and CCRF-CEM), we observed that J87-Dxd bound to CD7 was internalized into T-ALL cells. Moreover, J87-Dxd treatment significantly induced the apoptosis of Jurkat and CCRF-CEM cells. The IC50 (half-maximal inhibitory concentration) value of J87-Dxd against CCRF-CEM obtained by CCK-8 assay was 6.3 nM. Finally, to assess the antitumor efficacy of a J87-Dxd in vivo, we established T-ALL mouse models and treated mice with J87-Dxd or J87. The results showed that on day 24 after tumor inoculation, all mice treated with J87 or PBS died, whereas the survival rate of mice treated with J87-Dxd was 80%. H&E staining showed no significant organic changes in the heart, liver, spleen, lungs and kidneys of all mice. In summary, we demonstrated that the novel anti-CD7 ADC (J87-Dxd) had a potent and selective effect against CD7-expressing T-All cells both in vitro and in vivo, and could thus be expected to be further developed as a new drug for the treatment of T-ALL or other CD7-expression tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China.
- Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Förderung
- National Natural Science Foundation of China
- 1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University
- the Frontiers Medical Center, Tianfu Jincheng Laboratory Foundation
- the Major scientific and technological achievements transformation project, Ningxia Hui Autonomous Region
- the Post-Doctor Research Project, West China Hospital, Sichuan University
- Frontiers Medical Center, Tianfu Jincheng Laboratory Foundation
- Major scientific and technological achievements transformation project, Ningxia Hui Autonomous Region
- Post-Doctor Research Project, West China Hospital, Sichuan University
Zitieren
APA
Wang, S., Zhang, R., Zhong, K., Guo, W., & Tong, A. (2024). An Anti-CD7 Antibody–Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL). Biomolecules, 14(1), 106. https://doi.org/10.3390/biom14010106
Vancouver
Wang S, Zhang R, Zhong K, Guo W, Tong A. An Anti-CD7 Antibody–Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL). Biomolecules. 2024;14(1):106. doi:10.3390/biom14010106
BibTeX
@article{Wang2024,
author = {Wang, Shiqi and Zhang, Ruyuan and Zhong, Kunhong and Guo, Wenhao and Tong, Aiping},
title = {An Anti-CD7 Antibody–Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL)},
journal = {Biomolecules},
year = {2024},
volume = {14},
number = {1},
pages = {106},
doi = {10.3390/biom14010106}
}
EUVIMED